Matinas BioPharma to Present at the LD Micro Invitational on June 2, 2015

Presentation With Live Webcast at 3:00 p.m. PDT / 6:00 p.m. EDT

BEDMINSTER, N.J., May 28, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), a clinical-stage biopharmaceutical company principally focused on the development of targeted therapeutics for the treatment of infectious diseases, today announced that it will be presenting at the LD Micro Invitational being held June 1-3, 2015, at the Luxe Sunset Boulevard, Los Angeles, CA.

As part of his presentation, Roelof Rongen, President and Chief Executive Officer at Matinas BioPharma, will discuss the topline results from the pharmacokinetic and pharmacodynamic study of the Company's cardiovascular and metabolic product candidate MAT9001 on Tuesday, June 2, 2015, at 3:00 p.m. PDT / 6:00 p.m. EDT. Mr. Rongen will also review the clinical development strategy for MAT2203, a novel lipid-crystal nano-particle orally delivered formulation of Amphotericin B for the treatment of invasive fungal infections, and MAT2501, an early-stage program to treat gram-negative bacterial infections using an orally available formulation of Amikacin, a broad spectrum aminoglycoside.

A live webcast of the presentation will be available on the Events page of the Investor Relations section of the Company's website (www.matinasbiopharma.com). A webcast replay will be available approximately two hours after the presentation ends and will be accessible for one month.

About the LD Micro Invitational

LD Micro is an internet-based financial newsletter firm that provides self-directed investors information on selected public companies that in the opinion of LD Micro have great investment potential. The Invitational has grown from a small gathering five years ago, to one of the pre-eminent events in the micro-cap space. The firm also hosts the LD Micro Main Event in December. LD Micro is a non-registered investment advisor. For more information, please visit www.ldmicro.com.

About MAT9001

MAT9001 is a proprietary prescription-only omega-3 fatty acid-based composition, comprising docosapentaenoic acid (DPA) and other omega-3 fatty acids, which is under development for therapeutic applications with severe hypertriglyceridemia (TG>500 mg/dL) as the lead indication. Promising pre-clinical studies with DPA and MAT9001 indicate distinctive therapeutic response properties. In the fourth quarter of 2014, Matinas BioPharma filed an IND for MAT9001 with FDA. The Company believes that its development program and related clinical investigations may yield an improved therapeutic profile compared to existing therapies, based on MAT9001's differentiating mechanistic features associated with its unique composition.

About Matinas BioPharma

Matinas BioPharma is a clinical-stage biopharmaceutical company with a principal focus on identifying and developing novel and targeted pharmaceutical products for the treatment of various infectious diseases, with additional programs developing therapies to treat cardiovascular and metabolic conditions. Led by an experienced management team and a board of directors with a history of building pharmaceutical companies, Matinas BioPharma is focused on creating highly differentiated, safe and efficacious therapies utilizing its expertise in drug formulation and development in order to address significant unmet medical needs. Matinas BioPharma's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulations. For more information, please visit www.matinasbiopharma.com and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.

Forward Looking Statements: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's strategic focus and the future development of its product candidates and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.

CONTACT: Investor and Media Contact
         Jenene Thomas
         Investor Relations and Corporate Communications Advisor
         Jenene Thomas Communications, LLC
         Phone: +1 (908) 938-1475
         Email: jthomas@matinasbiopharma.com

Released May 28, 2015